Results 181 to 190 of about 24,341 (292)

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.

open access: yesKidney International, 2020
E. Rondeau   +60 more
semanticscholar   +1 more source

Ocular Manifestations in Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab: A Case Report and Review of the Literature. [PDF]

open access: yesCureus
Flindris K   +6 more
europepmc   +1 more source

Comprehensive Approach to Genetic Analysis and Therapy in Patient with Recurrence Atypical Hemolytic Uremic Syndrome

open access: bronze, 2012
Yoshiaki Sawada   +8 more
openalex   +1 more source

A case of Atypical Hemolytic Uremic Syndrome

open access: yesScholars Journal of Medical Case Reports, 2016
Rajesh Kumar   +3 more
openaire   +1 more source

Anti-C5 as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Living-Related Kidney Transplantation

open access: bronze, 2013
Miquel Blasco Pelícano   +6 more
openalex   +1 more source

Hypertensive Emergency and Atypical Hemolytic Uremic Syndrome Associated with Cocaine Use: A Diagnostic and Therapeutic Challenge. [PDF]

open access: yesDiseases
Jiménez Mayor E   +7 more
europepmc   +1 more source

A Novel Atypical Hemolytic Uremic Syndrome–Associated Hybrid CFHR1/CFH Gene Encoding a Fusion Protein That Antagonizes Factor H–Dependent Complement Regulation

open access: bronze, 2014
Elisabetta Valoti   +9 more
openalex   +1 more source

Case report - atypical hemolytic uremic syndrome triggered by influenza B [PDF]

open access: gold, 2017
Robin Kobbe   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy